Abstract: Provided is a pharmaceutical formulation. The pharmaceutical formulation comprises an anti-GREM1 antibody, a buffer, a stabilizer, a surfactant, and optionally an antioxidant. The pharmaceutical formulation provided herein could maintain the stability of the anti-GREM1 antibody after long-term storage, storage at high temperature (e.g., 40° C.), storage at room temperature, vibration and/or multiple freezing and thawing cycles. Provided are the use of the pharmaceutical formulation in prevention and/or treatment of GREM1 related diseases, especially cancers (e.g., GREM1 related cancers), and a method for preparing the pharmaceutical formulation.

Abstract: Provided are a protein comprising a PD-L1 binding moiety linked to a TGF R binding moiety, an IL-1 binding moiety, an immunostimulating polypeptide (such as soluble LAG3 or soluble CD4) or a CD47 binding moiety, and a pharmaceutical preparation thereof, a preparation method thereof and the use thereof.

Abstract: The present invention provides a PEGylated and fatty acid grafted chitosan oligosaccharide comprising a structural unit represented by the following Formula (I) and a structural unit represented by the following Formula (II) and synthesize method, wherein the chitosan oligosaccharide has a molecular weight of less than 200,000 Da, and a degree of deacetylation of 70%-100%, and part of free amino groups of chitosan oligosaccharide chain are replaced by a fatty acid or PEG, where n refers to degree of polymerization of the PEG, and R is an alkyl group having 11-21 carbon atoms. The grafting ratio of fatty acids is 1%-50%, and the grafting ratio of PEG is 0.05%-50%. The present invention also comprise a pharmaceutical composition comprising the PEGylated and fatty acid grafted chitosan oligosaccharide as a carrier, and use of the PEGylated and fatty acid grafted chitosan oligosaccharide in preparation of a pharmaceutical composition.

Abstract: The present invention provides a PEGylated and fatty acid grafted chitosan oligosaccharide comprising a structural unit represented by the following Formula (I) and a structural unit represented by the following Formula (II) and synthesize method, wherein the chitosan oligosaccharide has a molecular weight of less than 200,000 Da, and a degree of deacetylation of 70%-100%, and part of free amino groups of chitosan oligosaccharide chain are replaced by a fatty acid or PEG, where n refers to degree of polymerization of the PEG, and R is an alkyl group having 11-21 carbon atoms. The grafting ratio of fatty acids is 1%-50%, and the grafting ratio of PEG is 0.05%-50%. The present invention also comprise a pharmaceutical composition comprising the PEGylated and fatty acid grafted chitosan oligosaccharide as a carrier, and use of the PEGylated and fatty acid grafted chitosan oligosaccharide in preparation of a pharmaceutical composition.